Chronic graft-versus-host disease: Update on pathobiology, biomarkers, and evolving treatment algorithms
Cell Transplantation · 2026-07 · 35
DOI: 10.1177/09636897261471702 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Transplantation, online erschienen am 22.07.2026. Verfasst von Yibo Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China & Liangzhu Laboratory, Han…. Hauptthemen laut MEDLINE: Graft vs Host Disease, Biomarkers, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Chronic graft-versus-host disease (cGVHD) remains the leading cause of late non-relapse mortality and long-term disability after allogeneic hematopoietic cell transplantation (allo-HCT), affecting 30–70% of long-term survivors. Despite its substantial morbidity and the toxicities associated with prolonged corticosteroid use, therapeutic advances have accelerated considerably. This review synthesizes current mechanistic insights and clinical evidence within the framework of the well-established three-phase pathogenesis model of cGVHD. Phase 1 (early inflammation) involves tissue injury and innate immune activation; Phase 2 (months 2–12) is characterized by impaired central and peripheral tolerance with aberrant B- and T-cell responses; Phase 3 (>1 year) features macrophage-driven fibrosis and end-organ damage. Recognizing that these phases are conceptual and frequently overlap in clinical practice, we explore the alignment of contemporary biomarkers with each phase—ST2/CXCL9 (Phase 1), BAFF/autoantibodies (Phase 2), and MMP3/TGF-β (Phase 3)—and discuss how FDA-approved agents (ibrutinib, ruxolitinib, belumosudil, axatilimab) may target phase-specific pathways. A conceptual, risk-stratified treatment algorithm is proposed to link pathobiology to clinical decision-making, with the important caveat that biomarker-guided selection remains investigational and currently complements, rather than replaces, comprehensive clinical assessment. Notably, the adoption of prophylaxis and upfront strategies to prevent cGVHD has substantially reduced cGVHD incidence in modern cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China & Liangzhu Laboratory, Hangzhou, China.
- Institute of Hematology, Zhejiang University, Hangzhou, China.
- Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, China.
- Department of Hematology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, China.
ORCID-Profile: Yi Luo
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Wu, Y., Yuan, X., Lin, J., & Luo, Y. (2026). Chronic graft-versus-host disease: Update on pathobiology, biomarkers, and evolving treatment algorithms. Cell Transplantation, 35. https://doi.org/10.1177/09636897261471702
Vancouver
Wu Y, Yuan X, Lin J, Luo Y. Chronic graft-versus-host disease: Update on pathobiology, biomarkers, and evolving treatment algorithms. Cell Transplantation. 2026;35. doi:10.1177/09636897261471702
BibTeX
@article{Wu2026,
author = {Wu, Yibo and Yuan, Xiaolin and Lin, Jinya and Luo, Yi},
title = {Chronic graft-versus-host disease: Update on pathobiology, biomarkers, and evolving treatment algorithms},
journal = {Cell Transplantation},
year = {2026},
volume = {35},
doi = {10.1177/09636897261471702}
}
EUVIMED